Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TAS2R14 | Q9NYV8 | 11/20 | 0.53 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122533 | 0.87 | APLNR (0.59) | APLNRALDH1A1TAS2R14PTGESTAS2R8 | |
| SCHEMBL30200646 | 0.83 | ALDH1A1 (0.50) | APLNRALDH1A1TAS2R14PTGESTAS2R8 | |
| SCHEMBL30200719 | 0.82 | ALDH1A1 (0.49) | APLNRALDH1A1TAS2R14PTGESTAS2R8 | |
| SCHEMBL30200470 | 0.81 | ALDH1A1 (0.48) | APLNRALDH1A1TAS2R14PTGESTAS2R8 | |
| SCHEMBL6122831 | 0.80 | APLNR (0.71) | APLNRALDH1A1TAS2R14PTGESTAS2R8 | |
| SCHEMBL7350174 | 0.80 | ALDH1A1 (0.81) | ALDH1A1TAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL22119485 | 0.77 | APLNR (0.55) | APLNRALDH1A1TAS2R14 | |
| SCHEMBL16235820 | 0.76 | APLNR (0.65) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL23688601 | 0.76 | APLNR (0.52) | APLNRALDH1A1TAS2R14PTGESTAS2R8 | |
| SCHEMBL23688600 | 0.76 | APLNR (0.52) | APLNRALDH1A1TAS2R14PTGESTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| EP-4479388-A1 | ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023154905-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | APLNR 4781/4885ALDH1A1 3001/4885TAS2R14 2634/4885 |
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | SCN5A, SCN2B, SCN1B | APLNR 2384/4885ALDH1A1 2274/4885TAS2R14 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.